Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Visningar
• 07/18/23
0
0
Bädda in
administrator
Prenumeranter
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna